Teledermatology

DeepX Diagnostics Inc.'s DermoSight Receives FDA Clearance for Teledermatology Screening of Suspect Skin Cancer Lesions

Retrieved on: 
Tuesday, June 6, 2023

WASHINGTON, June 6, 2023 /PRNewswire/ -- DeepX Diagnostics Inc., the skin cancer teledermatology and diagnostics company, announced today that its digital dermatoscope DermoSightTM received clearance from the US Food and Drug Administration (FDA) for teledermatology screening of suspect skin cancer lesions in the United States. The company is now ready to enter the US market on the back of over 180 thousand assessments in pharmacies and primary care clinics in Europe.

Key Points: 
  • DeepX Diagnostics Inc. to enter US market, having already performed over 180,000 skin lesions assessments in pharmacy and primary care to date in Europe.
  • WASHINGTON, June 6, 2023 /PRNewswire/ -- DeepX Diagnostics Inc., the skin cancer teledermatology and diagnostics company, announced today that its digital dermatoscope DermoSightTM received clearance from the US Food and Drug Administration (FDA) for teledermatology screening of suspect skin cancer lesions in the United States.
  • DermoSight is currently cleared to acquire skin lesion images for teledermatology assessment, like existing digital dermatoscopes.
  • It will help people with skin lesions of concern receive early diagnosis and effective treatment of skin cancer," said Christian Horn, the CEO at DeepX Diagnostics.

DeepX Diagnostics Inc.'s DermoSight Receives FDA Clearance for Teledermatology Screening of Suspect Skin Cancer Lesions

Retrieved on: 
Tuesday, June 6, 2023

WASHINGTON, June 6, 2023 /PRNewswire/ -- DeepX Diagnostics Inc., the skin cancer teledermatology and diagnostics company, announced today that its digital dermatoscope DermoSightTM received clearance from the US Food and Drug Administration (FDA) for teledermatology screening of suspect skin cancer lesions in the United States. The company is now ready to enter the US market on the back of over 180 thousand assessments in pharmacies and primary care clinics in Europe.

Key Points: 
  • DeepX Diagnostics Inc. to enter US market, having already performed over 180,000 skin lesions assessments in pharmacy and primary care to date in Europe.
  • WASHINGTON, June 6, 2023 /PRNewswire/ -- DeepX Diagnostics Inc., the skin cancer teledermatology and diagnostics company, announced today that its digital dermatoscope DermoSightTM received clearance from the US Food and Drug Administration (FDA) for teledermatology screening of suspect skin cancer lesions in the United States.
  • DermoSight is currently cleared to acquire skin lesion images for teledermatology assessment, like existing digital dermatoscopes.
  • It will help people with skin lesions of concern receive early diagnosis and effective treatment of skin cancer," said Christian Horn, the CEO at DeepX Diagnostics.

Telemedicine Technologies and Services Market is Predicted to Rise at a CAGR of 13.8% during the Forecast Period, observes TMR Study

Retrieved on: 
Thursday, June 23, 2022

Future market outlook for telemedicine technologies and services estimates the market to rise at CAGR of 13.8% during the forecast period, from 2022 to 2031.

Key Points: 
  • Future market outlook for telemedicine technologies and services estimates the market to rise at CAGR of 13.8% during the forecast period, from 2022 to 2031.
  • The global telemedicine technologies and services market is likely to surpass valuation of US$ 526.7 Bn by 2031.The global telemedicine technologies and services market is likely to be propelled by the increasing use of telemedicine technologies and services in several specializedfieldssuch as cardiology,gynecology, dermatology,and neurology.
  • Telemedicine technologies and services market demand analysis predict that using telecommunication technology, telemedicine has been quite effective in treating patients at a faraway place.
  • By 2031, the services category is expected to account for a significant market share for telemedicine technologies and services.

Telemedicine Technologies and Services Market is Predicted to Rise at a CAGR of 13.8% during the Forecast Period, observes TMR Study

Retrieved on: 
Thursday, June 23, 2022

Future market outlook for telemedicine technologies and services estimates the market to rise at CAGR of 13.8% during the forecast period, from 2022 to 2031.

Key Points: 
  • Future market outlook for telemedicine technologies and services estimates the market to rise at CAGR of 13.8% during the forecast period, from 2022 to 2031.
  • The global telemedicine technologies and services market is likely to surpass valuation of US$ 526.7 Bn by 2031.The global telemedicine technologies and services market is likely to be propelled by the increasing use of telemedicine technologies and services in several specializedfieldssuch as cardiology,gynecology, dermatology,and neurology.
  • Telemedicine technologies and services market demand analysis predict that using telecommunication technology, telemedicine has been quite effective in treating patients at a faraway place.
  • By 2031, the services category is expected to account for a significant market share for telemedicine technologies and services.

Collaboration Between Smile CDR, MedX and Blanc Labs to Advance Global Evolution of Teledermatology

Retrieved on: 
Wednesday, May 4, 2022

TORONTO, May 04, 2022 (GLOBE NEWSWIRE) -- Smile CDR Inc., a leading health data and integration company, in collaboration with MedX Health Corp., a global leader in teledermatology, and its technology partner, Blanc Labs , today announced the interoperability of the MedX artificial intelligence (AI)-based teledermatology screening technology, DermSecure .

Key Points: 
  • TORONTO, May 04, 2022 (GLOBE NEWSWIRE) -- Smile CDR Inc., a leading health data and integration company, in collaboration with MedX Health Corp., a global leader in teledermatology, and its technology partner, Blanc Labs , today announced the interoperability of the MedX artificial intelligence (AI)-based teledermatology screening technology, DermSecure .
  • By providing a consistent, easy to implement and rigorous mechanism for exchanging data between healthcare applications, Smile CDR collaborated with Blanc Labs' engineers to power MedX's DermSecure platform.
  • At Blanc Labs, we partner for success: we constantly seek out and build ecosystem partnerships that bring our clients added value."
  • Headquartered in Toronto, Blanc Labs serves the Americas through operations in Toronto, New York, Bogota, and Buenos Aires.

US & Canada Skin Cancer Dermatology Market Report 2022-2030 Featuring Firefly, SkinIO, Canfield Scientific, FotoFinder, 3Gen, MetaOptima, Agilent Technologies, SkinVision, Speclipse, Skin Analytics - ResearchAndMarkets.com

Retrieved on: 
Monday, April 4, 2022

The U.S. & Canada skin cancer dermatology market size is expected to reach USD 3,395.97 million By 2030, registering a CAGR of 5.5%.

Key Points: 
  • The U.S. & Canada skin cancer dermatology market size is expected to reach USD 3,395.97 million By 2030, registering a CAGR of 5.5%.
  • The growing usage of smartphones and the development of smartphone compatible dermatoscopes are the factors anticipated to fuel the market growth.
  • Skin biopsy is the most widely used test for skin cancer and thus, accounted for the largest market share in 2019.
  • Some of the key market players are Firefly; SkinIO, Canfield Scientific, Inc., FotoFinder Systems, Inc., 3Gen, MetaOptima, Agilent Technologies, SkinVision, Speclipse, Inc., Skin Analytics..

MedX Health Announces Addition of Two New Screening Services Locations in Ottawa

Retrieved on: 
Thursday, January 27, 2022

Teledermatology company MedX Health Corp. ("MedX" or the "Company") (TSXV: MDX) is pleased to announce the launch of MedX Screening Services to be offered at two locations in Ottawa, Canada ProMed Pharmacy, an independent, pharmacist owned pharmacy enterprise, and Dura Wellness Clinic a retail, clinical focused esthetic services group.

Key Points: 
  • Teledermatology company MedX Health Corp. ("MedX" or the "Company") (TSXV: MDX) is pleased to announce the launch of MedX Screening Services to be offered at two locations in Ottawa, Canada ProMed Pharmacy, an independent, pharmacist owned pharmacy enterprise, and Dura Wellness Clinic a retail, clinical focused esthetic services group.
  • Both locations will now offer MedX scanning services and accept walk-in patients.
  • "ProMed Pharmacy, under the Leadership of Lubna Fawaz, is a perfect model of modern health care delivery as it integrates many services and, most importantly, telehealth services on demand for their patients.
  • ProMed Pharmacy now offering MedX Health Dermatological Screening Services:
    Dura Wellness Clinic is now offering MedX Health Dermatological Screening Services:
    MedX continues to focus on expanding its DermSecure Screening Platform network across North America.

MedX Health Corp. Announces Addition of Three New Screening Services Locations Across Ontario

Retrieved on: 
Monday, January 17, 2022

The partnership with TMC is the first launch of the MedX DermSecure screening platform within Canada's primary physician clinic network.

Key Points: 
  • The partnership with TMC is the first launch of the MedX DermSecure screening platform within Canada's primary physician clinic network.
  • Providing skin cancer screenings quickly and efficiently addresses patients' concerns over the current long wait times.
  • MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its SIAscopy on DermSecure telemedicine platform, utilizing its SIAscopy technology.
  • SIAscopy is also imbedded in its products SIAMETRICS, SIMSYS, and MoleMate, which MedX manufactures in its ISO 13485 certified facility.

Cosmetic Bootcamp begins the dialogue about diversity in dermatology.

Retrieved on: 
Tuesday, July 13, 2021

ASPEN, Colo., July 13, 2021 /PRNewswire/ -- At the 17th Annual Cosmetic Bootcamp, Dr. Jacob Beer outlined the disparities in dermatologic care in darker skin patients not only in the delivery of care but also in opportunities to become dermatologists.

Key Points: 
  • ASPEN, Colo., July 13, 2021 /PRNewswire/ -- At the 17th Annual Cosmetic Bootcamp, Dr. Jacob Beer outlined the disparities in dermatologic care in darker skin patients not only in the delivery of care but also in opportunities to become dermatologists.
  • During the pandemic, Dr. Beer worked on dozens of projects to use teledermatology to deliver high quality skin care and increase access to care.
  • Over the course of several months, it became apparent that huge disparities exist in the delivery of dermatologic care to skin of color patients.
  • One source of this disparity appears to be rooted in the lack of skin of color dermatologists with whom patients can relate.

Hims & Hers Completes Acquisition of Apostrophe

Retrieved on: 
Wednesday, July 7, 2021

Hims & Hers Health, Inc. (Hims & Hers, NYSE: HIMS), the multi-specialty telehealth platform focused on providing modern personalized health and wellness experiences to consumers, today announced it has finalized the acquisition of teledermatology specialist, Apostrophe.

Key Points: 
  • Hims & Hers Health, Inc. (Hims & Hers, NYSE: HIMS), the multi-specialty telehealth platform focused on providing modern personalized health and wellness experiences to consumers, today announced it has finalized the acquisition of teledermatology specialist, Apostrophe.
  • With this acquisition, Hims & Hers gains a trusted partner with expertise in charting this new future, as well as a leadership team that will help take our dermatology business to the next level.
  • As previously announced, the entire Apostrophe team, which includes world-class dermatology experts, will be joining Hims & Hers to help run the companys growing dermatology business line.
  • Apostrophe Chief Executive Officer and Co-Founder Ben Holber will become CEO of the Hims & Hers dermatology business line, reporting directly to Hims & Hers Chief Operating Officer Melissa Baird.